	US 12,187,725 B2
	Tricyclic urea compounds as JAK2 V617F inhibitors
Yanran Ai, West Chester, PA (US); Yu Bai, Claymont, DE (US); Joseph Barbosa, Lambertville, NJ (US); Hao Feng, Glen Mills, PA (US); Leah C. Konkol, Newark, DE (US); Xun Liu, Glenn Mills, PA (US); Jun Pan, Media, PA (US); Haisheng Wang, Hockessin, DE (US); Liangxing Wu, Wilmington, DE (US); Wenqing Yao, Chadds Ford, PA (US); and Eddy W. Yue, Landenberg, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Aug. 24, 2023, as Appl. No. 18/237,535.
Application 18/237,535 is a continuation of application No. 17/365,789, filed on Jul. 1, 2021, granted, now 11,780,840.
Claims priority of provisional application 63/047,483, filed on Jul. 2, 2020.
Claims priority of provisional application 63/164,302, filed on Mar. 22, 2021.
Prior Publication US 2024/0150354 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/437 (2006.01); C07D 471/14 (2006.01); C07D 519/00 (2006.01)

CPC C07D 471/14 (2013.01) [C07D 519/00 (2013.01); C07B 2200/05 (2013.01)]

42 Claims

1. A method of treating a myeloproliferative disorder selected from polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post polycythemia vera myelofibrosis in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound, which is 7-(3-methoxy-1-methyl-1H-pyrazol-4-yl)-3-methyl-8-(1-methyl-1H-indazol-5-yl)-1-(tetrahydro-2H-pyran-4-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one, or a pharmaceutically acceptable salt thereof.